To determine the potential media-related effects, we evaluated drug responses in two commercial lung cancer cell lines: HCC827, harboring an amplification of EGFR and exon 19 deletion [24], and H1869, a squamous cell carcinoma cell line with unknown EGFR status [25]. The gene discussed is EGFR; the disease is lung carcinoma.